Chani Maher (Becker)
Ph.D. 2016
E-MAIL: [email protected]
Thesis Title:
Molecular Mechanisms Underlying the Failures of Therapeutics in the Treatment of Malignant Glioma
Undergraduate Institution and Major/Degree:
State University of New York at Buffalo, B.S., Biomedical Sciences, 2010
Current Position:
Q-State Biosciences
Senior Director, Search and Evaluation
Previous Position(s):
Director of Business Operations, Pairnomix
Major Advisor(s):
David Largaespada, Ph.D.
Research Description:
Blood-brain barrier manipulation, preclinical modeling of brain tumors, and cancer genomics.
Lab Rotations:
- Virginia Seybold
- Harry Orr
- John Ohlfest
Courses Taken Beyond the Core Courses:
- PHCL 5110 - Pharmacology
- MICA 8004 - Cancer Biology
- MICA 8003 -Immunity & Immunopathology
Selected Publications:
- Hexum JK, Becker CM, Kempema AM, Ohlfest JR, Largaespada DA, Harki DA. Parthenolide prodrug LC-1 slows growth of intracranial glioma. Bioorg Med Chem Lett. 2015;25(12):2493-5.
- Becker CM, Oberoi RK, McFarren SJ, Muldoon DM, Pafundi DH, Pokorny JL, Brinkmann DH, Ohlfest JR, Sarkaria JN, Largaespada DA, Elmquist WF. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro Oncol. 2015 Sep;17(9):1210-9.